For this article:

5 Apr 2026·Source: The Hindu
2 min
EconomyInternational RelationsNEWS

India's Pharma Exports Show Resilience Despite War and Supply Chain Woes

Despite the West Asia crisis, India's pharmaceutical exports for FY26 are expected to remain positive, though supply chain disruptions for intermediates remain a challenge.

UPSC-MainsUPSC-Prelims
India's Pharma Exports Show Resilience Despite War and Supply Chain Woes

Photo by Omkar Ambre

Quick Revision

1.

India's pharma exports grew 5.6% up to February.

2.

Total pharma exports reached almost $28.29 billion up to February.

3.

FY25 saw record pharma exports of $30.47 billion.

4.

The FY25 record was aided by $1.6 billion medication invoicing to the U.S. in March ahead of a new tariff regime.

5.

The West Asia war impacted the energy supply chain.

6.

The war affected the availability of certain pharma intermediates and solvents.

7.

Pharmaceuticals are a priority sector for the Indian government.

8.

The government is working to alleviate supply chain dependency and diversify export markets.

9.

Import levies have been cut to facilitate sourcing from other geographies.

Key Dates

February (up to which exports grew)March (crucial for FY26 numbers, also when FY25 invoicing happened)FY25 (record exports)FY26 (current financial year for projections)

Key Numbers

@@5.6%@@ (export growth up to February)@@$28.29 billion@@ (exports up to February)@@$26.79 billion@@ (exports a year ago)@@$30.47 billion@@ (record exports in FY25)@@$1.6 billion@@ (medication invoiced to U.S. in March FY25)@@$32 billion@@ (FY26 export target)

Visual Insights

India's Pharma Exports: FY26 Outlook

Key statistics and projections for India's pharmaceutical exports in FY26, highlighting resilience amidst global challenges.

Projected Pharma Exports (FY26)
~$29 billion

Indicates sustained growth and market position despite geopolitical and supply chain disruptions.

Export Growth (Up to Feb FY26)
5.6%

Shows initial positive momentum before significant impact from West Asia war.

Mains & Interview Focus

Don't miss it!

The Commerce Ministry's cautious optimism regarding India's pharmaceutical exports for FY26, despite ongoing geopolitical tensions, underscores a critical aspect of India's economic resilience. While a 5.6% growth up to February is commendable, the underlying vulnerabilities in the global supply chain, particularly concerning energy and chemical intermediates, demand a more robust strategic response than mere reactive measures.

India's pharmaceutical sector, often termed the 'pharmacy of the world,' holds immense strategic importance, not just for export revenue but for global health security. The Patents Act of 1970 laid the groundwork for a thriving generic drug industry, enabling India to become a major supplier of affordable medicines. This historical policy foresight has positioned the sector uniquely to navigate global challenges, yet over-reliance on specific regions for Active Pharmaceutical Ingredients (APIs) and key intermediates remains a persistent chink in its armor.

The West Asia conflict's impact on energy supply chains, consequently affecting crucial pharma inputs like solvents, is a stark reminder of this dependency. The government's declaration of pharmaceuticals as a priority sector and its efforts to prioritize LPG supplies and cut import levies are necessary short-term interventions. However, these measures, while providing immediate relief, do not address the systemic issues of supply chain concentration.

A long-term strategy must prioritize aggressive diversification of sourcing, coupled with substantial investment in domestic manufacturing capabilities for critical intermediates. The Production Linked Incentive (PLI) scheme for pharmaceuticals is a step in this direction, but its implementation needs accelerated and targeted focus on reducing import dependency for high-volume, high-value inputs. Furthermore, India must actively forge new trade alliances and strengthen existing ones to create redundant supply routes, ensuring that future geopolitical shocks do not derail this vital sector's growth trajectory.

View Detailed Summary

Summary

Despite global conflicts like the war in West Asia, India's medicine exports are still expected to grow. The government is actively supporting the pharmaceutical industry by ensuring they get necessary supplies and find new markets, even though some raw materials are harder to obtain due to global disruptions.

Commerce Ministry and Pharmexcil officials express cautious optimism that India's pharmaceutical exports for FY26 will likely remain in positive territory, despite challenges from the West Asia war. While exports grew 5.6% up to February, the war has impacted the energy supply chain, affecting the availability of certain intermediates and solvents for the pharma industry. The government has assured that pharmaceuticals are a priority sector and is working to alleviate supply chain dependencies and diversify export markets.

Source Articles

RS

About the Author

Richa Singh

Public Policy Enthusiast & UPSC Analyst

Richa Singh writes about Economy at GKSolver, breaking down complex developments into clear, exam-relevant analysis.

View all articles →